All relevant data are within the paper and its Supporting Information files and also from <http://www.way2drug.com/cell-line/>.

Introduction {#sec001}
============

Oncology diseases are one of the main causes of death in the world \[[@pone.0191838.ref001]\]. Despite the fact that the development of antineoplastic agents is a main area for the biggest pharmaceutical companies (<http://spotfire.tibco.com/en/demos/pharma-pipeline-analysis.aspx>), the complexity of tumours and their histological, morphological and genetic diversity require the creation of new potent and safe drugs. Notwithstanding the progress in cell-based screening technology, experimental *in vivo* screening of anticancer drug-candidates through dozens of millions of natural and synthetic chemical compounds is rather expensive and time-consuming \[[@pone.0191838.ref002]\]. Different *in vitro* and *in silico* tools were proposed to reduce the cost of such screening and to reveal possible mechanisms of the growth inhibition and killing of tumour cells \[[@pone.0191838.ref003]\]. The study of the cytotoxicity of chemicals against tumour cell lines is widespread in the early stages of drug development, drug repositioning and cancer research \[[@pone.0191838.ref004]\]. NCI60, a 60 human tumour cell line anticancer drug screening panel, is one of the most well-known assays developed by the National Cancer Institute in the late 1980s for anticancer drug screening to replace the use of transplantable animal tumours \[[@pone.0191838.ref005]\]. Although the NCI has screened anticancer compounds for dozens of years, only approximately 70,000 compounds were estimated \[[@pone.0191838.ref005]\]. Since then, hundreds of cancer cell lines covering tissues and the histological variety of tumours have been developed for anticancer screening. Thus, the Genomics of Drug Sensitivity in Cancer project provides the cytotoxicity data for 138 drugs tested on 714 cancer cell lines (October 2013) \[[@pone.0191838.ref006],[@pone.0191838.ref007]\], and the Center for Molecular Therapeutics provides a panel with 1200 human cancer cell lines (CMT1000) \[[@pone.0191838.ref008]\]. Despite such progress, these tools are still rather expensive and are only used by a limited number of scientists for a limited number of chemicals. Therefore, there is a clear need for computer-based tools for virtual drug screening and an evaluation of the selective cytotoxic effect of chemical compounds on cancer cell lines. There are several approaches to developing such tools:

1.  (Q)SAR approach---analysis of "structure-cytotoxicity" relationships \[[@pone.0191838.ref009]--[@pone.0191838.ref014]\];

2.  Connectivity map approach---comparison of drug-induced gene signatures given on tumour cells \[[@pone.0191838.ref015]--[@pone.0191838.ref019]\];

3.  Network pharmacology approach---analysis of known drug-target interactions \[[@pone.0191838.ref020]--[@pone.0191838.ref023]\];

4.  Machine learning techniques for revealing relations between cell line cytotoxicity (IC50, IG50) and microarray data \[[@pone.0191838.ref024]--[@pone.0191838.ref027]\].

Despite the variety in the proposed methods and successful cases of their application, all of them require significant supplementary intellectual and technological efforts or additional experimental studies (e.g., in a case of the use of microarray data). The approaches related to the analysis of microarray data cannot be used for the virtual screening of compounds that have not been synthesized yet and that have no microarray data. Moreover, the mean accuracy (AUC) of the CMap approach validated on an independent set is approximately 0.61 for antineoplastic drugs \[[@pone.0191838.ref028]\]. The most published QSAR-based methods for the prediction of chemical tumour cell line cytotoxicity aimed to create QSAR models for calculating the IC50 or IG50 values for the single cell line \[[@pone.0191838.ref013]\], cell lines belonging to an appropriate tissue \[[@pone.0191838.ref011],[@pone.0191838.ref012]\] or without the determination of the particular cell line \[[@pone.0191838.ref010]\]. Only Menden and co-authors created QSAR models for 608 tumour cell lines from different tissues. The coefficient of determination R2 for the predicted IC50 values was 0.72 and 0.64 in an 8-fold cross-validation and an independent blind test, respectively \[[@pone.0191838.ref009]\]. However, their models were limited in applicability domain because they were based only on the data for 111 drugs tasted in the framework of the Genomics of Drug Sensitivity in Cancer project \[[@pone.0191838.ref009]\]. It is the smallest part of the known experimental data on chemical cytotoxicity. Moreover, none of the authors that predicted cytotoxicity against cancer cell lines predicted the cytotoxicity against human normal cell lines.

The recent development of freely available recourses, such as ChEMBL \[[@pone.0191838.ref029]\] and PubChem \[[@pone.0191838.ref030]\], containing experimental data from the biological testing of chemicals (including the cytotoxicity data of chemicals against tumour and normal cell lines) gives us an opportunity to use these data as an estimation of cell line cytotoxicity for new chemicals. Because these data are highly heterogenic and were obtained in different experimental conditions, it is likely that only kNN and classification SAR modelling can be used. PASS (Prediction of Activity Spectra for Substances) is a software related to the classification QSAR methods for predicting the biological activity of chemicals based on their 2D structure, which has been in development by the authors for many years for its use in predicting the biological activity on different levels of hierarchy of biological systems, including the mechanisms of actions (interaction with targets) and general effects (e.g., anti-inflammatory action, antihypertensive, antiepileptic, nootropic effects) \[[@pone.0191838.ref031]--[@pone.0191838.ref035]\]. We previously showed the applicability of PASS for predicting the carcinogenicity of drug-like organic compounds \[[@pone.0191838.ref036],[@pone.0191838.ref037]\]. Because the cell line cytotoxicity of chemicals may be considered a type of biological activity, we used PASS for predicting cell line cytotoxicity. The successful use of PASS in the prediction of cytotoxicity for 24 breast cancer cell-lines was earlier demonstrated, when 49 compounds from more than 1 million commercially available samples of compounds were selected on the basis of the prediction results of breast cancer cell line cytotoxicity and an interaction with potential antineoplastic drug targets \[[@pone.0191838.ref038]\]. Experimental testing of the 49 selected compounds revealed nine new compounds with cytotoxicity against the MDA-MB-231 and MCF7 breast cancer cell lines with the IC50 value equal to 0.8 μM at the most active compound \[[@pone.0191838.ref038]\]. The aim of the current study was to create and validate the SAR models for predicting the cytotoxicity of chemicals against tumour and normal human cell lines belonging to different tissues based on the PASS approach and the ChEMBL cytotoxicity data and to implement these SAR models as a freely available web-service.

Materials and methods {#sec002}
=====================

PASS (Prediction of Activity Spectra for Substances) approach {#sec003}
-------------------------------------------------------------

PASS provides simultaneous predictions for many types of biological activities (activity spectrum) based on the structure of drug-like compounds \[[@pone.0191838.ref031]--[@pone.0191838.ref035]\]. In PASS, biological activities are described qualitatively (active or inactive). The activity spectrum of a chemical compound is the set of different biological activity types that reflect the results of the compound's interaction with various biological entities. We consider that the cell line cytotoxicity of compounds is a biological activity because this effect is a response to the drug action and relates to the drug's structure. The algorithm of the activity spectrum estimation is based on the naive Bayes approach with some significant enhancements \[[@pone.0191838.ref031],[@pone.0191838.ref032]\].

The molecular structure is represented by the set of unique sub-structural atom-centric Multilevel Neighbourhoods of Atoms (MNA) descriptors of the first and second levels. These descriptors are a linear notation of atom-centred fragments in the structure of an organic molecule \[[@pone.0191838.ref039]\]. They are based on the molecular structure representation, which includes the hydrogen atoms according to the valences and partial charges of the atoms and does not specify the types of bonds. An example of the structural presentation by MNA descriptors for Sorafenib (used for the treatment of renal cell and hepatocellular carcinomas) is shown in [S1 Fig](#pone.0191838.s001){ref-type="supplementary-material"} of Supplements. The MNA descriptors are generated and prediction is executed only if the molecule's structure corresponds to the following criteria:

-   Each atom in a molecule must be presented by an atomic symbol from the periodic table. Symbols of unspecified atom A, Q, \*, or R group labels are not allowed.

-   Each bond in a molecule must be a covalent bond represented by single, double or triple bond types only.

-   The structure must include three or more carbon atoms.

-   The structure must include only one component.

-   The structure must be neutralized.

-   The absolute molecular weight of a compound must be less than 1250.

Since MNA descriptors do not represent the stereochemical peculiarities of the molecule, the substances with stereochemically different structures are formally considered to be equivalent.

A leave-one-out cross-validation for all predictable types of biological activity and all substances in the PASS training set provides an estimate of the PASS prediction accuracy during the training procedure. The accuracy criterion ROC AUC (the Area Under the ROC Curve) is used. It is the estimate of the probability that positive and negative examples (active and inactive compounds) that are arbitrarily chosen from a validation set may be classified correctly by the prediction.

The predicted activity spectrum in PASS is represented by a list of activities with probabilities «to be active» ***Pa*** and «to be inactive» ***Pi***. The list of predicted activities is arranged in descending order according to ***Pa****--****Pi*** values. Thus, the more probable activity types are at the top of the list. If the user chooses a higher value of ***Pa*** as a cut-off for selection of probable activities, the chance to confirm the predicted activities by the experiment is also high, but many existing activities will be lost. For instance, if ***Pa***\>0.5 is used as a threshold, about half of the real activities will be lost; for ***Pa***\>0.7, the portion of lost activities is 70%, etc.

By definition, the probabilities ***Pa*** and ***Pi*** are measures that belong to both subsets of \"active\" and \"inactive\" compounds and the probabilities of the 1^st^ and 2^nd^ types of prediction error, respectively. These two interpretations of probabilities ***Pa*** and ***Pi*** are equivalent and can be used for interpreting the results of prediction. They can also be used for the construction of different criteria to predict the results of the analysis corresponding to the specific practical tasks.

Training dataset {#sec004}
----------------

The ChEMBL database was used as a resource for cytotoxicity data of chemicals \[[@pone.0191838.ref029]\]. The database was chosen because of its convenience, free access, standardization and curation of the data. The twenty third version of the ChEMBL (ChEMBL_23) loaded into the MySQL database (<http://dev.mysql.com/>) was used. The script for the generation of the training sets was written in PHP language. ChEMBL_23 contained data for more than 1.7 million compounds, with information regarding their structures and interactions with over 11.5 thousand targets, including human tumour and normal cell lines. Two training sets were created from the ChEMBL data. One of the training sets contained the data on chemical cytotoxicity against human tumour cell lines, and the one was for human normal cell lines. The names of the cell-lines were used as in ChEMBL to provide links to the experimental data. The data from ChEMBL and Cellosaurus were used to distinguish cancer cell lines from non-cancer ones. Database of Cross-Contaminated or Misidentified Cell Lines was used to find in ChEMBL and to exclude from our training set misidentified cell lines where no authentic stock was ever found \[[@pone.0191838.ref040]\].

Structure Data File (SDF) format was used to save the extracted information. Single small molecular-weight organic compounds with electroneutral structures were selected during the creation of the training sets. The IG50 (half maximal inhibitory growth), IC50 (half maximal inhibitory concentration) and % inhibition (of activity) values were analysed. The compounds were considered active if the IG50 and IC50 values were less than 10000 nM or if the percent of inhibition was higher than 50%. All compounds were considered inactive for the appropriate cell line if they were not active for this cell line according to the above-mentioned criteria. The selected cell lines contained at least 3 active and 10 inactive compounds. All the records of compounds that were simultaneously classified as active and inactive for the appropriate cell line were excluded.

Results {#sec005}
=======

Creation and validation of SAR models for the prediction of cell line cytotoxicity {#sec006}
----------------------------------------------------------------------------------

The training set of 59,882 unique structures of compounds was created based on the experimental data from the ChEMBL (version 23), which reflects the current knowledge about the cytotoxic substances to 943 human cell lines. This training set was used to train PASS for the creation of classification models of "structure-cytotoxicity" relationships. Only cell lines for which the cytotoxicity was predicted with the accuracy of prediction (AUC) higher than 0.8 were selected. The average accuracy of prediction calculated by a leave-one-out cross-validation (LOO CV) procedure was 0.948 for the cytotoxicity prediction for 27 normal cell lines ([Table 1](#pone.0191838.t001){ref-type="table"}) and was 0.930 for 278 cancer cell lines ([S1 Table](#pone.0191838.s002){ref-type="supplementary-material"}). The average accuracy of prediction calculated by a 20-fold cross-validation procedure was similar to the result given for the LOO CV: 0.947 for cytotoxicity prediction for 27 normal cell lines ([Table 1](#pone.0191838.t001){ref-type="table"}) and 0.927 for 278 cancer cell lines ([S1 Table](#pone.0191838.s002){ref-type="supplementary-material"}). The small difference between the accuracy of prediction given by the LOO CV and the 20-fold CV procedures shows the creation of robust SAR models.

10.1371/journal.pone.0191838.t001

###### Normal cell lines with predicted accuracy calculated by leave-one-out cross-validation (AUC LOO CV) and 20-fold cross-validation (AUC 20-fold CV) procedures.
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  No         Cell line     Type of cell line                                    Tissue/organ                      N      AUC LOO CV   AUC 20-fold CV
  ---------- ------------- ---------------------------------------------------- --------------------------------- ------ ------------ ----------------
  1          AG1523        Fibroblast                                           Fibroblast                        25     0.971        0.971
  2          BJ            Foreskin fibroblast                                  Foreskin                          37     0.889        0.862
  3          CRL-7065      Fibroblast                                           Skin                              9      0.926        0.927
  4          Detroit 551   Embryonic skin                                       Skin                              30     0.962        0.962
  5          HaCaT         Keratinocyte                                         Skin                              218    0.978        0.978
  6          HASMC         Aortic smooth muscle                                 Muscle                            26     0.999        0.999
  7          HEK293        Embryonic kidney fibroblast                          Kidney                            711    0.922        0.921
  8          HEL 299       Fibroblast                                           Lung                              3      0.889        0.891
  9          HFF           Foreskin fibroblast                                  Skin                              171    0.974        0.974
  10         HFL1          Human foetal lung fibroblast                         Lung                              3      1.000        1.000
  11         HMEC          Microvascular endothelial cell                       Breast                            64     0.948        0.950
  12         HS27          Fibroblast                                           Skin                              40     0.971        0.972
  13         HUVEC         Umbilical vein endothelial cell                      Endothelium                       999    0.958        0.958
  14         IMR-90        Embryonic lung fibroblast                            Lung                              14     0.860        0.862
  15         MRC5          Embryonic lung fibroblast                            Lung                              392    0.921        0.920
  16         MT2           Lymphocyte (HTLV-1 producing cell line)              Blood                             93     0.968        0.969
  17         NFF           Fibroblast                                           Skin                              57     0.978        0.978
  18         NHDF          Fibroblast                                           Skin                              51     0.947        0.941
  19         PBMC          Peripheral blood mononuclear cell                    Blood                             1194   0.973        0.972
  20         PrEC          Prostate epithelial cell                             Prostate                          4      0.802        0.804
  21         RPTEC         Renal proximal tubule epithelial cells               Kidney                            8      0.998        0.998
  22         SKW 6.4       B lymphocyte; Epstein-Barr virus (EBV) transformed   Haematopoietic, lymphoid tissue   39     1.000        1.000
  23         TERT-RPE1     Retinal pigmented epithelial cell                    Retina                            10     0.903        0.904
  24         WI-38         Embryonic lung fibroblast                            Lung                              150    0.939        0.939
  25         WI-38 VA13    Embryonic lung fibroblast                            Lung                              6      0.965        0.965
  26         WIL2          Lymphoblastoid cell                                  Haematopoietic, lymphoid tissue   31     1.000        1.000
  27         WIL2-NS       Lymphoblastoid cell                                  Haematopoietic, lymphoid tissue   44     0.961        0.953
  **Mean**   **0.948**     **0.947**                                                                                                  

N---number of active compounds in the training set

[Table 2](#pone.0191838.t002){ref-type="table"} represents the cancer cell lines' distribution in 27 various organs or tissue types. More than 10000 compounds were actives for the colon (18 423), breast (15 716) and lung (14 439) tumour cell lines, probably because many cell lines are known for these organs and they are the objects of intensive study.

10.1371/journal.pone.0191838.t002

###### Distribution of cancer cell lines in various organs or tissue types with data on mean accuracy of prediction calculated by leave-one-out cross-validation (AUC LOO CV) and 20-fold cross-validation (AUC 20-fold CV) procedures for cell lines from the Organ/tissue.
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  No   Organ/tissue                         Number of cell lines   N       AUC LOO CV   AUC 20-fold CV
  ---- ------------------------------------ ---------------------- ------- ------------ ----------------
  1    Adrenal cortex                       1                      11      0.844        0.846
  2    Blood                                26                     7232    0.950        0.950
  3    Bone                                 8                      443     0.902        0.901
  4    Brain                                15                     3534    0.941        0.940
  5    Breast                               16                     15716   0.915        0.914
  6    Cervix                               3                      4425    0.935        0.934
  7    Colon                                26                     18423   0.948        0.947
  8    Germ cell, fibroblast                1                      58      0.993        0.992
  9    Haematopoietic and lymphoid tissue   16                     9540    0.914        0.912
  10   Head and neck                        4                      82      0.989        0.989
  11   Kidney                               11                     4678    0.904        0.902
  12   Large intestine                      1                      564     0.962        0.961
  13   Liver                                8                      3165    0.960        0.959
  14   Lung                                 38                     14439   0.915        0.911
  15   Nervous system                       3                      599     0.920        0.921
  16   Ovarium                              24                     7408    0.942        0.941
  17   Pancreas                             14                     1417    0.921        0.919
  18   Prostate                             7                      7286    0.935        0.933
  19   Skin                                 26                     7386    0.910        0.908
  20   Small intestine                      1                      8       1.000        1.000
  21   Soft tissue                          1                      338     0.903        0.899
  22   Stomach                              14                     1884    0.948        0.948
  23   Testicle                             1                      16      0.986        0.986
  24   Thyroid                              2                      166     0.919        0.913
  25   Upper aerodigestive tract            2                      64      0.981        0.792
  26   Urinary tract                        6                      583     0.913        0.908
  27   Uterus                               3                      138     0.954        0.954

N---number of active compounds in the training set.

The AUC range for the different cell lines was from 0.800 (DMS-114---lung carcinoma) to 1.000 (e.g., MOH---cisplatin-resistant ovarian carcinoma cells). The most accurate prediction among organs with several cell lines was obtained for four head and neck cell lines (AUC 0.989; 82 active compounds in the training set), two upper aerodigestive tract cell lines (AUC 0.981; 64), and eight liver cell lines (AUC 0.960; 3165). The colon, breast, and lung cell lines also showed a mean accuracy of prediction of AUC \> 0.9 (0.948, 0.915, 0.915, respectively), but no strict correlation was found between the number of substances in the training set or the number of cell lines in the category and accuracy of prediction.

CLC-Pred (Cell Line Cytotoxicity Predictor) web service {#sec007}
-------------------------------------------------------

A freely available web-service PASS CLC Pred for the prediction of cytotoxicity of chemicals against tumour and normal human cell lines from different tissues was created based on the abovementioned PASS models (<http://www.way2drug.com/Cell-line/>). The example of the prediction of cell line cytotoxicity for Sorafenib (a kinase inhibitor used for the treatment of liver, kidney and thyroid cancers) is shown in [Fig 1](#pone.0191838.g001){ref-type="fig"}. It displays that one of the top predicted tumour cell line is liver carcinoma, which coincides with its known therapeutic application. The prediction results also include the cytotoxicity against several melanoma cell lines, and some publications confirm this activity (e.g., Pécuchet with co-authors \[[@pone.0191838.ref041]\]).

![The prediction results for Sorafenib with the web-service.](pone.0191838.g001){#pone.0191838.g001}

The chemical structure for the prediction of cytotoxicity can be uploaded using the following three different modes: input SMILES strings \[[@pone.0191838.ref042]\], upload a file in a "mol file' format \[[@pone.0191838.ref043]\] or draw in Marvin JS applet. The prediction results display two tables with the probable profiles of cytotoxicity (for tumour and normal cell lines). Each table includes the Pa and Pi values, the short and full names of cell lines, and the name of the tissue. The table with the prediction results against the tumour cell lines also includes the types of tumours. The prediction results can be sorted by clicking on the titles of the columns. The short names of cell lines have a link to a record from ChEMBL with the description of the cell line and experimental data of the compounds tested on this cell line. The prediction results can be saved as \*.sdf, \*.csv or \*.pdf files.

The web-service uses a MySQL server to store data and PHP and HTML codes to implement the main interface. The Python script was used to produce the independent sub-processes for generating the input to the prediction program and data processing.

Repositioning of drugs used for breast cancer treatment {#sec008}
-------------------------------------------------------

Using the CLC-Pred service we analysed four drugs launched for the treatment of breast cancer and studied them for new therapeutic applications against other types of tumours. All information on the names, structures, stage of study and therapeutic applications was obtained from the Thomson Reuters (currently, Clarivate Analytics) Integrity Database ([Table 3](#pone.0191838.t003){ref-type="table"}).

10.1371/journal.pone.0191838.t003

###### Known and new predicted applications for drugs launched for the treatment of breast cancer.
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  Name                                                                                                                                                Known therapeutic groups of application                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    Phases of study                                                                                                                                                                                                                                                                                                                                                     Possible new applications based on prediction of cancer cell line cytotoxicity
  --------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------
  Doxorubicin                                                                                                                                         cancer: non-small cell lung[\*](#t003fn002){ref-type="table-fn"}, breast[\*](#t003fn002){ref-type="table-fn"}, brain[\*](#t003fn002){ref-type="table-fn"}, liver[\*](#t003fn002){ref-type="table-fn"}, head and neck                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       *launched*---breast cancer[\*](#t003fn002){ref-type="table-fn"}                                                                                                                                                                                                                                                                                                     bone cancer, stomach cancer, kidney cancer, skin cancer, tumours of haematopoietic and lymphoid tissue
  *phase II*---head and neck cancer                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  
  *preclinical*---liver cancer[\*](#t003fn002){ref-type="table-fn"} (hepatocellular carcinoma), hepatoblastoma[\*](#t003fn002){ref-type="table-fn"}                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  
  Gemcitabine                                                                                                                                         cancer: small cell lung[\*](#t003fn002){ref-type="table-fn"}, prostate[\*](#t003fn002){ref-type="table-fn"}, non-small cell lung[\*](#t003fn002){ref-type="table-fn"}, lung[\*](#t003fn002){ref-type="table-fn"}, cervical[\*](#t003fn002){ref-type="table-fn"}, neurologic[\*](#t003fn002){ref-type="table-fn"}, melanoma[\*](#t003fn002){ref-type="table-fn"}, breast[\*](#t003fn002){ref-type="table-fn"}, ovarian[\*](#t003fn002){ref-type="table-fn"}, brain[\*](#t003fn002){ref-type="table-fn"}, bladder[\*](#t003fn002){ref-type="table-fn"}, digestive/gastrointestinal[\*](#t003fn002){ref-type="table-fn"}, sarcoma[\*](#t003fn002){ref-type="table-fn"}, colorectal[\*](#t003fn002){ref-type="table-fn"}, renal[\*](#t003fn002){ref-type="table-fn"}, head and neck, pancreatic[\*](#t003fn002){ref-type="table-fn"}, endocrine, unspecified body location/system, female reproductive system; myeloid leukaemia[\*](#t003fn002){ref-type="table-fn"}, lymphoma[\*](#t003fn002){ref-type="table-fn"}, non-Hodgkin's lymphoma   *launched*--cancer: lung[\*](#t003fn002){ref-type="table-fn"} (non-small cell[\*](#t003fn002){ref-type="table-fn"}), pancreas[\*](#t003fn002){ref-type="table-fn"}, ovary[\*](#t003fn002){ref-type="table-fn"}, breast[\*](#t003fn002){ref-type="table-fn"}, lymphoma[\*](#t003fn002){ref-type="table-fn"}, bladder[\*](#t003fn002){ref-type="table-fn"}, biliary   osteosarcoma
  *phase III*---rhinopharyngeal cancer, medac cholangiocarcinoma, leiomyosarcoma                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     
  *phase II/III*---head and neck cancer                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              
  *phase II*---fallopian tube cancer, Hodgkin's lymphoma, T-cell lymphoma[\*](#t003fn002){ref-type="table-fn"}, peripheral                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           
  *phase I*---bladder cancer[\*](#t003fn002){ref-type="table-fn"} (urothelial carcinoma, transitional cell)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          
  Raloxifene                                                                                                                                          cancer: breast[\*](#t003fn002){ref-type="table-fn"}, prostate                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              *launched*---breast cancer[\*](#t003fn002){ref-type="table-fn"}                                                                                                                                                                                                                                                                                                     acute T-lymphoblastic leukemia
  *phase I---*prostate cancer (adenocarcinoma)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       
  Vinorelbine                                                                                                                                         cancer: multiple myeloma[\*](#t003fn002){ref-type="table-fn"}, prostate[\*](#t003fn002){ref-type="table-fn"}, non-small cell lung[\*](#t003fn002){ref-type="table-fn"}, neurologic[\*](#t003fn002){ref-type="table-fn"}, breast[\*](#t003fn002){ref-type="table-fn"}; solid tumours[\*](#t003fn002){ref-type="table-fn"}, non-Hodgkin's lymphoma                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           *launched*---cancer: breast[\*](#t003fn002){ref-type="table-fn"}, lung[\*](#t003fn002){ref-type="table-fn"} (non-small cell lung carcinoma[\*](#t003fn002){ref-type="table-fn"})                                                                                                                                                                                    small cell lung carcinoma, colon carcinoma, osteosarcoma, childhood acute myeloid leukaemia with maturation
  *phase II*--glioma                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 

*italic font*--phase of drug development;

\*--correct prediction by CLC-Pred web-service.

The prediction results, which are shown in the Supplements ([S2 Table](#pone.0191838.s003){ref-type="supplementary-material"}), were compared with known and newly studied therapeutic applications of these drugs. The sign '\*' shows that the prediction results of the drug include the predicted cell line cytotoxicity related to this application. For most of the known applications, the appropriate cell lines were predicted correctly. The last column displays new applications for these drugs given by the prediction of the cancer cell line cytotoxicity.

Discussion {#sec009}
==========

The ChEMBL database provides freely available experimental data on the cytotoxicity study of compounds against more than 1500 cell lines. These data allowed us to create reasonable classification SAR models for predicting the cytotoxicity of chemicals against 305 cell lines. Most of these cell lines (278) are different types of tumours related to the organs or tissue, which are of great interest in the development of new drugs or the repositioning of known drugs. ChEMBL includes much less information about the cytotoxicity of compounds against normal cell lines. Therefore, the number of classification models for the prediction of cytotoxicity of chemicals against normal cell lines is less. The models were created only for 27 normal cell-lines, which also belong to different organs or tissues. The ability to predict the cytotoxic action of compounds against normal cell lines is very important for estimating the safety of drug-candidates because many of the cytotoxic compounds that are used against tumour cell lines are often cytotoxic for normal cells and must be excluded from drug-candidates. The prediction of the cytotoxicity of chemicals against normal cell lines may be helpful for estimating the safety of drug-candidates for development in other therapeutic fields of application. The estimation of the general toxicity of compounds at the level of the organism may be given by our previously developed freely available web service for the prediction of rat acute toxicity (<http://www.way2drug.com/gusar/acutoxpredict.html>), which predicts the LD50 values for chemicals with oral, intravenous, intraperitoneal and subcutaneous routes of administration \[[@pone.0191838.ref044]\]. The PASS Online (<http://www.way2drug.com/PASSOnline/>) service may be used for predicting the possible molecular mechanisms of action related to the cytotoxic action of compounds \[[@pone.0191838.ref034]\].

During the analysis of the prediction results provided by the CLC-Pred service, one should remember that the prediction of cytotoxicity against each cell line is executed independently from other cell lines with a different accuracy of prediction. With less AUC accuracy calculated by the LOO CV, a greater number of false positive results will be in the prediction results for a given cell line. If one would like to reduce the number of false positive predictions, he (she) should increase the threshold of the Pa value. Together with the rules of interpretation of the prediction results described in the materials and methods, it should be noted that prediction results including the cytotoxicity against several cell lines from the same organ or tissue increase the probability of finding cytotoxic compounds acting on tumours located in that organ or tissue. The web service started working in 2016. Since then, several studies to assess the cytotoxicity of natural compounds have been conducted by independent researchers \[[@pone.0191838.ref045]--[@pone.0191838.ref048]\].

The traditional single target or multi-target based drug designs aim at estimating the interaction between the ligand and target(s). In this paradigm, some potential drug-candidates that display *in silico* or *in vitro* interactions with antineoplastic targets may not reveal the general cytotoxic effect on cell lines. Revealing the cell effects depends not only on the interaction with the targets but also on many other parameters, e.g., interaction with transporters, passage through a cell membrane, and regulation of signal and metabolic pathways, which depend on cell-line-specific cancer mutations and changes in gene expression. Therefore, the combination of the computational estimation of the cytotoxic effect of chemicals in different cell-lines together with the estimation of the ligand-target interactions provides a more effective method for the design of new antineoplastic drugs. An example of the application of such approach was recently provided in our publication on the search for new compounds with cytotoxicity against breast cancer cell lines \[[@pone.0191838.ref038]\].
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###### Sorafenib's molecular structure and its presentation by MNA descriptors.
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###### Tumour cell lines with predicted accuracy calculated by leave-one-out cross-validation (AUC LOO CV) and 20-fold cross-validation (AUC 20-fold CV) procedures.
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###### CLC-Pred prediction results for four drugs launched for treatment of breast cancer and studied for new therapeutic applications against other types of tumours.
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###### The script for the generation of SDF files of the training sets.
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###### The input file for Script.php with ChEMBL IDs and names of tumour cell lines for creation of SDF file of the training set.

(CSV)
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Click here for additional data file.

###### The input file for Script.php with ChEMBL IDs and names of non-tumour cell lines for creation of SDF file of the training set.

(CSV)
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Click here for additional data file.
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